There weren’t any S&P 500 earnings reactions yesterday…
But one recent move continues to stand out.
There’s a quiet resurgence happening in one of the market’s most forgotten corners: Genomics.
The industry has been left for dead after peaking during the 2020 to 2021 boom and suffering an 85% collapse.
But buried under the wreckage are a few real businesses making real progress.
One of them is Adaptive Biotechnologies $ADPT, a $1.6B biotech company on a mission to decode the immune system.
Their goal is simple but revolutionary: make the immune response a measurable, actionable source of insight for diagnosing and treating disease.
They’re already delivering on that promise through clonoSEQ, their flagship test for monitoring minimal residual disease in blood cancers.
This product is seeing strong clinical uptake and broader support from payers and regulators.
What’s even more exciting is who they’re building with.
They’ve partnered with Microsoft $MSFT to apply machine learning at scale to immune sequencing data.
In other words, they're combining AI and cloud computing with clinical-grade science.
And they’ve joined forces with Roche $RHHBY, one of the world’s largest pharmaceutical companies, to co-develop next-generation immune-driven diagnostics.
These aren’t speculative partnerships.
They’re with two of the most critical players in technology and pharma.
And the market is finally starting to reward their progress.
On May 2nd, the stock posted its best earnings reaction ever, jumping over 33% in a single session.
After years of pain, this name is back and better than ever.
Let’s break down the opportunity…
The Genomics reawakening 📉📈
The ARK Genomic Revolution ETF $ARKG was one of the biggest winners of the last cycle, surging over 670% from its 2016 low to its 2021 high.
Then came the crash, an 85% drawdown that decimated most genomic stocks and erased years of gains.
But now, something interesting is happening...
The ETF recently tried to break below the critical 22 level, which is a shelf of former support.
But the bears failed miserably...
Now, it's looking like an "oops" pattern.
With the buyers back in control of the short-term trend, we want to be prepared for a violent squeeze higher.
If ARKG can hold 22, it could mark a major sentiment shift, and possibly the early stages of a new rotation into genomics.
If so, we want to own the strongest names in this industry.
Mr. Market has picked a leader 🥇
One of the best-performing names in the space? Adaptive Biotechnologies.
The price has rallied by over 350% over the last year and shows no signs of slowing down.
On May 2nd, the stock posted its best earnings reaction ever, gapping higher on strong results and clear operating leverage.
The move launched the stock into fresh 52-week highs, and it hasn’t looked back.
The price action is sending a clear message: the market likes what this company is doing.
ADPT's growth is on fire 🔥
Adaptive Bio's core business, clonoSEQ, a minimal residual disease (MRD) test used to monitor cancer, is accelerating.
In Q1 2025, clinical testing revenue jumped 55% year-over-year, fueled by a record test volume.
Some key highlights:
U.S. test volumes climbed to 22,368
Ordering healthcare providers rose 31% YoY
Epic/EMR integrations reached 27
6 key payer contracts were renegotiated or closed
This isn’t just a product with traction.
It’s a business that’s scaling and earning buy-in from both providers and payers.
Here's the long-term setup 👇
Adaptive Bio has spent years building a textbook bearish-to-bullish reversal pattern.
The upper bound of this range coincides with the VWAP anchored to the all-time high.
After a year of strong price action and a blockbuster earnings reaction, the stock is right back at that key zone.
With improving fundamentals and clear institutional interest, we think this setup has the potential to break out and run.
The Genomics revolution may have taken a backseat the past few years, but if stocks like this are any indication, that may be changing fast.
We want to buy ADPT on strength above 11.50, betting on a brand-new uptrend that could take prices back to new all-time highs in the future.
Thank you for reading.
- The Beat Report Team
PS: AI is moving fast, and so is the tech reshaping how we live, work, and invest.
In Godspeed, Riley Rosebee highlights the companies driving the future — and the price levels that matter right now.
If you find our content valuable, we would greatly appreciate it if you could shareit with your friends, family, and colleagues. Your help in spreading the word is invaluable in supporting our work. Thank you to all of you who share!
